Literature DB >> 22728465

Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism.

Paul W Buehler1, Jin Hyen Baek, Christina Lisk, Ian Connor, Tim Sullivan, Douglas Kominsky, Susan Majka, Kurt R Stenmark, Eva Nozik-Grayck, Joe Bonaventura, David C Irwin.   

Abstract

Cell-free hemoglobin (Hb) exposure may be a pathogenic mediator in the development of pulmonary arterial hypertension (PAH), and when combined with chronic hypoxia the potential for exacerbation of PAH and vascular remodeling is likely more pronounced. We hypothesized that Hb may contribute to hypoxia-driven PAH collectively as a prooxidant, inflammatory, and nitric oxide (NO) scavenger. Using programmable micropump technology, we exposed male Sprague-Dawley rats housed under room air or hypoxia to 12 or 30 mg per day Hb for 3, 5, and 7 wk. Blood pressure, cardiac output, right ventricular hypertrophy, and indexes of pulmonary vascular remodeling were evaluated. Additionally, markers of oxidative stress, NO bioavailability and inflammation were determined. Hb increased pulmonary arterial (PA) pressure, pulmonary vessel wall stiffening, and right heart hypertrophy with temporal and dose dependence in both room air and hypoxic cohorts. Hb induced a modest increase in plasma oxidative stress markers (malondialdehyde and 4-hydroxynonenal), no change in NO bioavailability, and increased lung ICAM protein expression. Treatment with the antioxidant Tempol attenuated Hb-induced pulmonary arterial wall thickening, but not PA pressures or ICAM expression. Chronic exposure to low plasma Hb concentrations (range = 3-10 μM) lasting up to 7 wk in rodents induces pulmonary vascular disease via inflammation and to a lesser extent by Hb-mediated oxidation. Tempol demonstrated a modest effect on the attenuation of Hb-induced pulmonary vascular disease. NO bioavailability was found to be of minimal importance in this model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728465      PMCID: PMC3423829          DOI: 10.1152/ajplung.00074.2012

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  39 in total

1.  An improved process for the production of sterile modified haemoglobin solutions.

Authors:  F A Highsmith; C M Driscoll; B C Chung; M D Chavez; V W Macdonald; J M Manning; L E Lippert; R L Berger; J R Hess
Journal:  Biologicals       Date:  1997-09       Impact factor: 1.856

Review 2.  Role of nuclear factor kappaB in cardiovascular health and disease.

Authors:  Kim Van der Heiden; Simon Cuhlmann; Le A Luong; Mustafa Zakkar; Paul C Evans
Journal:  Clin Sci (Lond)       Date:  2010-02-23       Impact factor: 6.124

Review 3.  Artificial O2 carriers: status in 2005.

Authors:  Donat R Spahn; Roman Kocian
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

4.  Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

5.  A hemodynamic study of pulmonary hypertension in sickle cell disease.

Authors:  Florence Parent; Dora Bachir; Jocelyn Inamo; François Lionnet; Françoise Driss; Gylna Loko; Anoosha Habibi; Soumiya Bennani; Laurent Savale; Serge Adnot; Bernard Maitre; Azzedine Yaïci; Leila Hajji; Dermot S O'Callaghan; Pierre Clerson; Robert Girot; Frederic Galacteros; Gerald Simonneau
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

6.  Hydrogen peroxide-mediated ferrylhemoglobin generation in vitro and in red blood cells.

Authors:  C Giulivi; K J Davies
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

7.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

8.  A potential role for reactive oxygen species and the HIF-1alpha-VEGF pathway in hypoxia-induced pulmonary vascular leak.

Authors:  David C Irwin; Joe M McCord; Eva Nozik-Grayck; Ginny Beckly; Ben Foreman; Tim Sullivan; Molly White; Joseph T Crossno; Damian Bailey; Sonia C Flores; Susan Majka; Dwight Klemm; Martha C Tissot van Patot
Journal:  Free Radic Biol Med       Date:  2009-04-07       Impact factor: 7.376

Review 9.  Pulmonary hypertension in sickle cell disease: relevance to children.

Authors:  Gregory J Kato; Onyinye C Onyekwere; Mark T Gladwin
Journal:  Pediatr Hematol Oncol       Date:  2007 Apr-May       Impact factor: 1.969

10.  Hemoglobin induces the expression of indoleamine 2,3-dioxygenase in dendritic cells through the activation of PI3K, PKC, and NF-kappaB and the generation of reactive oxygen species.

Authors:  Nanako Ogasawara; Takashi Oguro; Toshitsugu Sakabe; Miyoko Matsushima; Osamu Takikawa; Ken-ichi Isobe; Fumihiko Nagase
Journal:  J Cell Biochem       Date:  2009-10-15       Impact factor: 4.429

View more
  25 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  Hemolysis-induced Lung Vascular Leakage Contributes to the Development of Pulmonary Hypertension.

Authors:  Olga Rafikova; Elissa R Williams; Matthew L McBride; Marina Zemskova; Anup Srivastava; Vineet Nair; Ankit A Desai; Paul R Langlais; Evgeny Zemskov; Marc Simon; Lawrence J Mandarino; Ruslan Rafikov
Journal:  Am J Respir Cell Mol Biol       Date:  2018-09       Impact factor: 6.914

3.  Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.

Authors:  Hagir B Suliman; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 4.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

5.  An Hb-mediated circulating macrophage contributing to pulmonary vascular remodeling in sickle cell disease.

Authors:  Katherine Redinus; Jin Hyen Baek; Ayla Yalamanoglu; Hye Kyung H Shin; Radu Moldova; Julie W Harral; Delaney Swindle; David Pak; Scott K Ferguson; Rachelle Nuss; Kathryn Hassell; Eva Nozik-Grayck; Andre F Palmer; Mehdi A Fini; Vijaya Karoor; Kurt R Stenmark; Paul W Buehler; David C Irwin
Journal:  JCI Insight       Date:  2019-08-08

6.  Hemoglobin-induced endothelial cell permeability is controlled, in part, via a myeloid differentiation primary response gene-88-dependent signaling mechanism.

Authors:  Christina Lisk; Doug Kominsky; Stefan Ehrentraut; Joe Bonaventura; Rachelle Nuss; Kathryn Hassell; Eva Nozik-Grayck; David C Irwin
Journal:  Am J Respir Cell Mol Biol       Date:  2013-10       Impact factor: 6.914

Review 7.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

8.  Elevation of plasma cell-free hemoglobin in pulmonary arterial hypertension.

Authors:  Evan L Brittain; David R Janz; Eric D Austin; Julie A Bastarache; Lisa A Wheeler; Lorraine B Ware; Anna R Hemnes
Journal:  Chest       Date:  2014-12       Impact factor: 9.410

9.  Effects of living at moderate altitude on pulmonary vascular function and exercise capacity in mice with sickle cell anaemia.

Authors:  Scott K Ferguson; Katherine Redinius; Ayla Yalamanoglu; Julie W Harral; Jin Hyen Baek; David Pak; Zoe Loomis; Daniel Hassell; Paul Eigenberger; Eva Nozik-Grayck; Rachelle Nuss; Kathryn Hassell; Kurt R Stenmark; Paul W Buehler; David C Irwin
Journal:  J Physiol       Date:  2018-08-25       Impact factor: 5.182

Review 10.  Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both.

Authors:  Jeffrey D Marshall; Isabel Bazan; Yi Zhang; Wassim H Fares; Patty J Lee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-01-18       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.